-+ 0.00%
-+ 0.00%
-+ 0.00%

NanoViricides reports $3.64 million net cash use for quarter ended Sept. 30, 2026

PUBT·11/17/2026 13:45:54
Listen to the news
NanoViricides reports $3.64 million net cash use for quarter ended Sept. 30, 2026
  • NanoViricides reported approximately $2.98 million in cash and cash equivalents at September 30, 2026, with current liabilities of approximately $3.1 million.
  • Net cash utilized totaled approximately $3.64 million for the quarter, including nonrecurring research and development expenditures for Phase II clinical trials.
  • NV-387 oral gummies entered separate Phase II trials for Ebola Bundibugyo and mpox, with sufficient funding projected to complete both.
  • Funding remains insufficient to sustain operations through November 16, 2027, under planned objectives; management will adjust its business plan to available resources.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611170845ACCESSWRNAPR_____1252522) on November 17, 2026, and is solely responsible for the information contained therein.